Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma

Abstract Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseli...

Full description

Bibliographic Details
Main Authors: Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Hänel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Format: Article
Language:English
Published: Nature Publishing Group 2023-01-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-022-00772-9

Internet

https://doi.org/10.1038/s41408-022-00772-9

Similar Items